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SCIENTIFIC OPINION 
Scientific Opinion on the substantiation of health claims related to 
Saccharomyces boulardii ATY-SB-101 (BCCM/MUCL 53837) (ID 1010, 




EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
2, 3
 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
Following a request from the European Commission, the Panel on Dietetic Products, Nutrition and Allergies was 
asked to provide a scientific opinion on health claims pursuant to Article 13.1 of Regulation (EC) No 1924/2006 
in the framework of further assessment related to Saccharomyces boulardii ATY-SB-101 and the following 
claimed effects: "maintains and restores the natural flora" and "modulating both innate and adaptive host 
immunity to respond against pathogen infection". The food constituent that is the subject of the claims, 
Saccharomyces boulardii ATY-SB-101 (BCCM/MUCL 53837), is not sufficiently characterised. On the basis of 
the data presented, the Panel concludes that a cause and effect relationship cannot be established between the 
consumption of Saccharomyces boulardii ATY-SB-101 (BCCM/MUCL 53837) and the proposed claimed 
effects. 
© European Food Safety Authority, 2012 
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Saccharomyces boulardii, ATY-SB-101, microorganisms, health claims. 
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SUMMARY 
Following a request from the European Commission, the Panel on Dietetic Products, Nutrition and 
Allergies was asked to provide a scientific opinion on a list of health claims pursuant to Article 13 of 
Regulation (EC) No 1924/2006. The Commission has agreed with EU Member States that a certain 
number of Article 13 health claims would be eligible for further assessment by EFSA in order to be 
able to take a final decision on whether or not to include these claims in the list of permitted health 
claims. This opinion addresses the scientific substantiation of health claims in relation to 
Saccharomyces boulardii ATY-SB-101 (BCCM/MUCL 53837) and the following claimed effects: 
"maintains and restores the natural flora" and "modulating both innate and adaptive host immunity to 
respond against pathogen infection". The scientific substantiation is based on the information 
provided by the competent Authority of Belgium for further assessment of this claim. 
The food constituent that is the subject of the health claims is Saccharomyces boulardii ATY-SB-101 
(BCCM/MUCL 53837) related to the following claimed effects: "maintains and restores the natural 
flora" and "modulating both innate and adaptive host immunity to respond against pathogen 
infection".  
The Panel notes that the information provided did not allow concluding that the strain that is the 
subject of the claims (ATY-SB-101) can be identified as S. cerevisiae var boulardii. The Panel 
considers that Saccharomyces boulardii ATY-SB-101 (BCCM/MUCL 53837) is not sufficiently 
characterised. 
On the basis of the data presented, the Panel concludes that a cause and effect relationship cannot be 
established between the consumption of Saccharomyces boulardii ATY-SB-101 (BCCM/MUCL 
53837) and the proposed claimed effects. 
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INTRODUCTION 
The Commission has agreed with EU Member States that a certain number of Article 13 health claims 
would be eligible for further assessment by EFSA in order to be able to take a final decision on 
whether or not to include these claims in the list of permitted health claims. These claims include 
already assessed claims related to micro-organisms which the Panel considered to be not sufficiently 
characterised and claims for which the NDA Panel concluded that there was insufficient evidence to 
establish a cause and effect relationship between the consumption of the food and the claimed effect. 
Following an opinion of the NDA Panel on a health claim pursuant to Article 13 of Regulation (EC) 
No 1924/2006
4
 in which the Panel concluded that the data available were not sufficient to characterise 
Saccharomyces boulardii ATY-SB-101 (EFSA Panel on Dietetic Products Nutrition and Allergies 
(NDA), 2009), EFSA received additional information from the competent Authority of Belgium for 
further assessment of these claims. The information provided in the framework of further assessment 
for the health claims which are the subject of this opinion is tabulated in Appendix C. 
ASSESSMENT 
The approach used in the evaluation of Article 13(1) health claims is explained in the general 
guidance for stakeholders on the evaluation of Article 13.1, 13.5 and 14 health claims
5
.  
In assessing each specific food/health relationship that forms the basis of a health claim the NDA 
Panel considers the extent to which:   
1. the food/constituent is defined and characterised;  
2. the claimed effect is defined and is a beneficial physiological effect (“beneficial to human health”);   
3. a cause and effect relationship is established between the consumption of the food/constituent and 
the claimed effect (for the target group under the proposed conditions of use).  
Substantiation of the claim is dependent on a favourable outcome of the assessment of 1, 2 and 3 
above. Thus, a cause and effect relationship is considered not to be established if the outcome of any 
one of these assessments is unfavourable.  
For a claim, each relationship between a food/constituent and a claimed effect is assessed separately, 
and individual assessments are combined, as appropriate, to form coherent opinions. 
1. Characterisation of the food/constituent (ID 1010, 1011) 
The food constituent that is the subject of the health claims is Saccharomyces boulardii ATY-SB-101 
(BCCM/MUCL 53837) related to the following claimed effects: "maintains and restores the natural 
flora" and "modulating both innate and adaptive host immunity to respond against pathogen 
infection".  
A culture collection number from the Belgian Co-ordinated Collections of (Agro) Industrial Fungi and 
Yeast Collection (BCCM/MUCL) is provided (MUCL 53837). The BCCM/MUCL is an 
internationally recognised culture collection, which has the status of an International Depositary 
                                                     
4  Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and 
health claims made on foods. OJ L 404, 30.12.2006, p. 9–25.  
5 EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA), 2011. General guidance for stakeholders on the 
evaluation of Article 13.1, 13.5 and 14 health claims. EFSA Journal, 9(4):2135, 24 pp. 
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Authority under the Budapest Treaty. In the MUCL, cultures can be deposited in a restricted-access 
collection for safe deposit or for patent purposes. 
The identification of the strain ATY-SB-101, which is the subject of the claim, at species level (as 
S. cerevisiae) was based on phylogenetic analyses of rDNA sequences (the D1/D2 region and the 5.8S 
rDNA internal transcribe spacer [ITS] region) and the mitochondrial CytC gene sequence. The Panel 
notes that these analyses allow the identification of the strain ATY-SB-101 with the species 
S. cerevisiae but not the discrimination between S. cerevisiae and S. cerevisiae var. boulardii.  
The characterisation of S. cerevisiae var. boulardii ATY-SB-101 at strain level was based on 
restriction analyses of two rDNA regions (ITS and 18S). The restriction analysis of the ITS region 
resulted in a unique DNA band, and that of the 18S rDNA in two bands. The Panel notes that 
comparative analysis of the DNA band profiles with those of a reference strain identified as 
S. cerevisiae var. boulardii, or references to publications showing the expected DNA profiles, were 
not provided, and therefore, it is not possible to conclude that the strain that is the subject of the 
claims (ATY-SB-101) can be identified as S. cerevisiae var boulardii.  
Three references were provided in the application related to the use of phenotypic and genotypic 
techniques for the identification of S. cerevisiae strains (Fietto et al., 2004; van der Aa Kuhle and 
Jespersen, 2003; van der Aa Kuhle et al., 2005), but none of these included data related to the strain 
that is the subject of the health claims (ATY-SB-101). 
The Panel considers that the food constituent, Saccharomyces boulardii ATY-SB-101 (BCCM/MUCL 
53837), which is the subject of the health claims, is not sufficiently characterised. 
The Panel concludes that a cause and effect relationship cannot be established between the 
consumption of Saccharomyces boulardii ATY-SB-101 (BCCM/MUCL 53837) and the proposed 
claimed effects. 
CONCLUSIONS  
On the basis of the data presented, the Panel concludes that: 
 The food constituent, Saccharomyces boulardii ATY-SB-101 (BCCM/MUCL 53837), which 
is the subject of the health claims, is not sufficiently characterised. 
 A cause and effect relationship cannot be established between the consumption of 
Saccharomyces boulardii ATY-SB-101 (BCCM/MUCL 53837) and the proposed claimed 
effects.  
DOCUMENTATION PROVIDED TO EFSA 
Health claims pursuant to Article 13 of Regulation (EC) No 1924/2006 for further assessment (No: 
EFSA-Q-2012-00156, EFSA-Q-2012-00157). The scientific substantiation is based on the information 
provided by the competent Authority of Belgium for further assessment of this claim (available at: 
http://www.efsa.europa.eu/en/topics/topic/article13.htm). 
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APPENDICES 
APPENDIX A 
BACKGROUND AND TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION 
The Regulation 1924/2006 on nutrition and health claims made on foods
6
 (hereinafter "the 
Regulation") entered into force on 19
th
 January 2007. 
Article 13 of the Regulation foresees that the Commission shall adopt a Community list of permitted 
health claims other than those referring to the reduction of disease risk and to children's development 
and health. This Community list shall be adopted through the Regulatory Committee procedure and 
following consultation of the European Food Safety Authority (EFSA). 
Health claims are defined as "any claim that states, suggests or implies that a relationship exists 
between a food category, a food or one of its constituents and health".  
In accordance with Article 13 (1) health claims other than those referring to the reduction of disease 
risk and to children's development and health are health claims describing or referring to:  
a) the role of a nutrient or other substance in growth, development and the functions of the 
body; or 
b) psychological and behavioural functions; or 
c) without prejudice to Directive 96/8/EC, slimming or weight-control or a reduction in the 
sense of hunger or an increase in the sense of satiety or to the reduction of the available 
energy from the diet. 
To be included in the Community list of permitted health claims, the claims shall be:  
(i) based on generally accepted scientific evidence; and 
(ii) well understood by the average consumer. 
Member States provided the Commission with lists of claims as referred to in Article 13 (1) by 31 
January 2008 accompanied by the conditions applying to them and by references to the relevant 
scientific justification. These lists have been consolidated into the list which forms the basis for the 
EFSA consultation in accordance with Article 13 (3).  
ISSUES THAT NEED TO BE CONSIDERED 
IMPORTANCE AND PERTINENCE OF THE FOOD
7
  
Foods are commonly involved in many different functions
8
 of the body, and for one single food many 
health claims may therefore be scientifically true. Therefore, the relative importance of food e.g. 
nutrients in relation to other nutrients for the expressed beneficial effect should be considered: for 
functions affected by a large number of dietary factors it should be considered whether a reference to 
a single food is scientifically pertinent.  
                                                     
6  OJ L12, 18/01/2007 
7  The term 'food' when used in this Terms of Reference refers to a food constituent, the food or the food category.  
8  The term 'function' when used in this Terms of Reference refers to health claims in Article 13(1)(a), (b) and (c).   
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It should also be considered if the information on the characteristics of the food contains aspects 
pertinent to the beneficial effect.  
SUBSTANTIATION OF CLAIMS BY GENERALLY ACCEPTABLE SCIENTIFIC EVIDENCE 
Scientific substantiation is the main aspect to be taken into account to authorise health claims. Claims 
should be scientifically substantiated by taking into account the totality of the available scientific 
data, and by weighing the evidence, and shall demonstrate the extent to which: 
(a) the claimed effect of the food is beneficial for human health, 
(b) a cause and effect relationship is established between consumption of the food and the 
claimed effect in humans (such as: the strength, consistency, specificity, dose-
response, and biological plausibility of the relationship), 
(c) the quantity of the food and pattern of consumption required to obtain the claimed 
effect could reasonably be achieved as part of a balanced diet, 
(d) the specific study group(s) in which the evidence was obtained is representative of the 
target population for which the claim is intended. 
EFSA has mentioned in its scientific and technical guidance for the preparation and presentation of 
the application for authorisation of health claims consistent criteria for the potential sources of 
scientific data. Such sources may not be available for all health claims. Nevertheless it will be 
relevant and important that EFSA comments on the availability and quality of such data in order to 
allow the regulator to judge and make a risk management decision about the acceptability of health 
claims included in the submitted list. 
The scientific evidence about the role of a food on a nutritional or physiological function is not 
enough to justify the claim. The beneficial effect of the dietary intake has also to be demonstrated. 
Moreover, the beneficial effect should be significant i.e. satisfactorily demonstrate to beneficially 
affect identified functions in the body in a way which is relevant to health. Although an appreciation 
of the beneficial effect in relation to the nutritional status of the European population may be of 
interest, the presence or absence of the actual need for a nutrient or other substance with nutritional or 
physiological effect for that population should not, however, condition such considerations. 
Different types of effects can be claimed. Claims referring to the maintenance of a function may be 
distinct from claims referring to the improvement of a function. EFSA may wish to comment whether 
such different claims comply with the criteria laid down in the Regulation. 
WORDING OF HEALTH CLAIMS 
Scientific substantiation of health claims is the main aspect on which EFSA's opinion is requested. 
However, the wording of health claims should also be commented by EFSA in its opinion. 
There is potentially a plethora of expressions that may be used to convey the relationship between the 
food and the function. This may be due to commercial practices, consumer perception and linguistic 
or cultural differences across the EU. Nevertheless, the wording used to make health claims should be 
truthful, clear, reliable and useful to the consumer in choosing a healthy diet. 
In addition to fulfilling the general principles and conditions of the Regulation laid down in Article 3 
and 5, Article 13(1)(a) stipulates that health claims shall describe or refer to "the role of a nutrient or 
other substance in growth, development and the functions of the body". Therefore, the requirement to 
Saccharomyces boulardii ATY-SB-101 (BCCM/MUCL 53837) 
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describe or refer to the 'role' of a nutrient or substance in growth, development and the functions of 
the body should be carefully considered. 
The specificity of the wording is very important. Health claims such as "Substance X supports the 
function of the joints" may not sufficiently do so, whereas a claim such as "Substance X helps 
maintain the flexibility of the joints" would. In the first example of a claim it is unclear which of the 
various functions of the joints is described or referred to contrary to the latter example which 
specifies this by using the word "flexibility". 
The clarity of the wording is very important. The guiding principle should be that the description or 
reference to the role of the nutrient or other substance shall be clear and unambiguous and therefore 
be specified to the extent possible i.e. descriptive words/ terms which can have multiple meanings 
should be avoided. To this end, wordings like "strengthens your natural defences" or "contain 
antioxidants" should be considered as well as "may" or "might" as opposed to words like 
"contributes", "aids" or "helps".  
In addition, for functions affected by a large number of dietary factors it should be considered 
whether wordings such as "indispensable", "necessary", "essential" and "important" reflects the 
strength of the scientific evidence. 
Similar alternative wordings as mentioned above are used for claims relating to different relationships 
between the various foods and health. It is not the intention of the regulator to adopt a detailed and 
rigid list of claims where all possible wordings for the different claims are approved. Therefore, it is 
not required that EFSA comments on each individual wording for each claim unless the wording is 
strictly pertinent to a specific claim. It would be appreciated though that EFSA may consider and 
comment generally on such elements relating to wording to ensure the compliance with the criteria 
laid down in the Regulation. 
In doing so the explanation provided for in recital 16 of the Regulation on the notion of the average 
consumer should be recalled. In addition, such assessment should take into account the particular 
perspective and/or knowledge in the target group of the claim, if such is indicated or implied. 
TERMS OF REFERENCE 
HEALTH CLAIMS OTHER THAN THOSE REFERRING TO THE REDUCTION OF DISEASE RISK AND TO 
CHILDREN'S DEVELOPMENT AND HEALTH 
EFSA should in particular consider, and provide advice on the following aspects:  
 Whether adequate information is provided on the characteristics of the food pertinent to the 
beneficial effect. 
 Whether the beneficial effect of the food on the function is substantiated by generally 
accepted scientific evidence by taking into account the totality of the available scientific data, 
and by weighing the evidence. In this context EFSA is invited to comment on the nature and 
quality of the totality of the evidence provided according to consistent criteria. 
 The specific importance of the food for the claimed effect. For functions affected by a large 
number of dietary factors whether a reference to a single food is scientifically pertinent.  
In addition, EFSA should consider the claimed effect on the function, and provide advice on the 
extent to which: 
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 the claimed effect of the food in the identified function is beneficial. 
 a cause and effect relationship has been established between consumption of the food and the 
claimed effect in humans and whether the magnitude of the effect is related to the quantity 
consumed. 
 where appropriate, the effect on the function is significant in relation to the quantity of the 
food proposed to be consumed and if this quantity could reasonably be consumed as part of a 
balanced diet.  
 the specific study group(s) in which the evidence was obtained is representative of the target 
population for which the claim is intended. 
 the wordings used to express the claimed effect reflect the scientific evidence and complies 
with the criteria laid down in the Regulation.  
When considering these elements EFSA should also provide advice, when appropriate: 
 on the appropriate application of Article 10 (2) (c) and (d) in the Regulation, which provides 
for additional labelling requirements addressed to persons who should avoid using the food; 
and/or warnings for products that are likely to present a health risk if consumed to excess. 
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related health claims (further assessment) 
 
12 EFSA Journal 2012;10(6):2722 
APPENDIX B 
EFSA DISCLAIMER 
The present opinion does not constitute, and cannot be construed as, an authorisation to the marketing 
of the food/food constituent, a positive assessment of its safety, nor a decision on whether the 
food/food constituent is, or is not, classified as foodstuffs. It should be noted that such an assessment 
is not foreseen in the framework of Regulation (EC) No 1924/2006. 
It should also be highlighted that the scope, the proposed wordings of the claims and the conditions of 
use as proposed in the Consolidated List may be subject to changes, pending the outcome of the 
authorisation procedure foreseen in Article 13(3) of Regulation (EC) No 1924/2006. 
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APPENDIX C 
Table 1.  Health claims related to Saccharomyces boulardii ATY-SB-101 (BCCM/MUCL 53837), including conditions of use, as proposed in the 
framework of further assessment. 
ID Food or Food constituent Health Relationship Proposed wording 
1010 Saccharomyces boulardii 
ATY-SB-101 (=MUCL 
53837) 
Saccharomyces boulardii is yeast closely related to Saccharomyces cerevisiae able to grow at 
37°C. It was isolated for the first time by Henri Boulard in 1923 from tropical fruits. S. boulardii 
has been shown to be non-pathogenic, non-systemic remaining in the gastrointestinal tract. It has 
been demonstrated that its consumption brings many beneficial effects for intestinal tract and was 
classified as a probiotic .  
The beneficial effect of Saccharomyces boulardii has been demonstrated by several clinical. 
So, Centina-Sauri et al. (1994) and Kurugöl et al. (2005) has demonstrated that S. boulardii 
maintains and restores the natural flora in the large and small intestine especially in the case of 
acute gastroenteritis. 
The beneficial effect has been also demonstrated in much other gastrointestinal affections such as 
(i) in recurrent Clostridium difficile infection, (ii) in irritable bowel syndrome, (iii) in 
inflammatory bowel disease, (iv) in travelers' diarrhea, and (v) in antibiotic-associated diarrhea. 
 Maintains intestinal 
microflora's balance; 
 probiotic regulates 
intestinal transit; 
 balances intestinal 
flora; 
 supports healthy 
digestive system. 
Conditions of use At least 10 E+8 CFU/day. The target population is the normal population and person with digestive troubles. It can be used to promote 
intestinal comfort/health. 
ID Food or Food constituent Health Relationship Proposed wording 
1011 Saccharomyces boulardii 
ATY-SB-101 (=MUCL 
53837) 
Saccharomyces boulardii is yeast closely related to Saccharomyces cerevisiae able to grow at 
37°C. It was isolated for the first time by Henri Boulard in 1923 from tropical fruits. S. boulardii 
has been shown to be non-pathogenic, non-systemic remaining in the gastrointestinal tract. It has 
been demonstrated that its consumption brings many beneficial effects for health and immune 
system and was classified as a probiotic.  
Several studies demonstrated that S. boulardii might induces a protective effect in modulating 
both innate and adaptive host immunity to respond against pathogen infection. 
 Helps to reinforce 
the natural defenses;  
 Stimulates the 
immune system;  
 Modulates the 
immune response; 
Conditions of use At least 10 E+8 CFU/day. The target population is the normal persons 
Saccharomyces boulardii ATY-SB-101 (BCCM/MUCL 53837) 
related health claims (further assessment) 
 
14 EFSA Journal 2012;10(6):2722 
GLOSSARY AND ABBREVIATIONS 
BCCM  Belgian Co-ordinated Collections of Micro-organisms 
CytC  Cytochrome complex 
DNA  Deoxyribonucleic acid 
ITS  Internal transcribe spacer 
MUCL  Mycothèque de l'Université catholique de Louvain 
rDNA  Ribosomal DNA 
 
 
